ArticleNeuro-oncology2023
Global survival trends for brain tumors, by histology: Analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3).
Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Childhood cancer survival in Africa, Asia, Latin America and the Caribbean, during 2008-2017 (SURVCAN-3): a population-based benchmarking study of 16 821 children.Journal of the National Cancer Institute · 2026Article
- Incidence of primary central nervous system tumors across age groups and histological groups in Osaka, Japan, 2011-2020.Journal of neuro-oncology · 2026Article
- Article
- The role of DNA methylation in directing treatment in medulloblastoma.Epigenomics · 2025Review
- Epidemiology of childhood cancer in Asia.EClinicalMedicine · 2025Review
- Mapping of current resources and models of care for paediatric cancer survivors in Asia: a multinational survey.BMJ global health · 2025Article
- Nanopore Sequencing Reveals Novel Alternative Splice Variants of EZH2 in Pediatric Medulloblastoma.Biomedicines · 2025Article
- Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM.Cancer discovery · 2025Article
- Medulloblastoma in Adolescents and Young Adults (AYA): Bridging Pediatric Paradigms and Adult Oncology Practice.Journal of clinical medicine · 2025Review
- Exploring neonatal brain tumors: a narrative review about epidemiology, classification, and management.Annals of medicine and surgery (2012) · 2025Review
- The effectiveness of kinesiology taping on dysphagia in brain tumor survivors after neurosurgery: study protocol for a pilot randomized controlled trial.Frontiers in medicine · 2025Article
- Epidemiology of malignant brain tumors in Genova, Italy. 1993-2017.Scientific reports · 2024Article
- EDA2R reflects the acute brain response to cranial irradiation in liquid biopsies.Neuro-oncology · 2024Article
- Glioma.Nature reviews. Disease primers · 2024Review
- Pediatric neuro-oncology in Latin America and the Caribbean: a gap to be filled.Frontiers in oncology · 2024Article
- Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years.Current pharmaceutical design · 2024Article
- Article
- Risk-Adapted Treatment Strategies with Pre-Irradiation Chemotherapy in Pediatric Medulloblastoma: Outcomes from the Polish Pediatric Neuro-Oncology Group.Children (Basel, Switzerland) · 2023Article
- Nanoparticle Strategies to Improve the Delivery of Anticancer Drugs across the Blood-Brain Barrier to Treat Brain Tumors.Pharmaceutics · 2023Review
- Expanding our knowledge of brain tumor overall survival trends at a global scale.Neuro-oncology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTumors of the central nervous system are among the leading causes of cancer-related death in children. Population-based cancer survival reflects the overall effectiveness of a health care system in managing cancer. Inequity in access to care world-wide may result in survival disparities.
methodsWe considered children (0-14 years) diagnosed with a brain tumor during 2000-2014, regardless of tumor behavior. Data underwent a rigorous, three-phase quality control as part of CONCORD-3. We implemented a revised version of the International Classification of Childhood Cancer (third edition) to control for under-registration of non-malignant astrocytic tumors. We estimated net survival using the unbiased nonparametric Pohar Perme estimator.
resultsThe study included 67,776 children. We estimated survival for 12 histology groups, each based on relevant ICD-O-3 codes. Age-standardized 5-year net survival for low-grade astrocytoma ranged between 84% and 100% world-wide during 2000-2014. In most countries, 5-year survival was 90% or more during 2000-2004, 2005-2009, and 2010-2014. Global variation in survival for medulloblastoma was much wider, with age-standardized 5-year net survival between 47% and 86% for children diagnosed during 2010-2014.
conclusionsTo the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors in children, by histology. We devised an enhanced version of ICCC-3 to account for differences in cancer registration practices world-wide. Our findings may have public health implications, because low-grade glioma is 1 of the 6 index childhood cancers included by WHO in the Global Initiative for Childhood Cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.